- Home
- SEMR vs MNKD Comparison
SEMR vs MNKD Comparison
Compare SEMR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- MNKD
- Stock Information
- Founded
- SEMR 2008
- MNKD 1991
- Country
- SEMR United States
- MNKD United States
- Employees
- SEMR N/A
- MNKD N/A
- Industry
- SEMR EDP Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- MNKD Health Care
- Exchange
- SEMR Nasdaq
- MNKD Nasdaq
- Market Cap
- SEMR 1.5B
- MNKD 1.4B
- IPO Year
- SEMR 2021
- MNKD 2004
- Fundamental
- Price
- SEMR $10.38
- MNKD $4.56
- Analyst Decision
- SEMR Buy
- MNKD Buy
- Analyst Count
- SEMR 8
- MNKD 6
- Target Price
- SEMR $17.00
- MNKD $8.92
- AVG Volume (30 Days)
- SEMR 514.0K
- MNKD 1.5M
- Earning Date
- SEMR 05-07-2025
- MNKD 05-08-2025
- Dividend Yield
- SEMR N/A
- MNKD N/A
- EPS Growth
- SEMR N/A
- MNKD 215.86
- EPS
- SEMR 0.05
- MNKD 0.10
- Revenue
- SEMR $396,021,000.00
- MNKD $297,595,000.00
- Revenue This Year
- SEMR $21.18
- MNKD $14.23
- Revenue Next Year
- SEMR $19.04
- MNKD $14.56
- P/E Ratio
- SEMR $219.99
- MNKD $46.04
- Revenue Growth
- SEMR 22.75
- MNKD 32.50
- 52 Week Low
- SEMR $7.90
- MNKD $4.17
- 52 Week High
- SEMR $18.74
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SEMR 56.95
- MNKD 38.80
- Support Level
- SEMR $9.38
- MNKD $4.42
- Resistance Level
- SEMR $10.58
- MNKD $5.05
- Average True Range (ATR)
- SEMR 0.40
- MNKD 0.18
- MACD
- SEMR 0.10
- MNKD 0.00
- Stochastic Oscillator
- SEMR 87.88
- MNKD 20.59
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.